Market Spotlight: Tumor Lysis Syndrome (TLS)
Market Spotlight: Tumor Lysis Syndrome (TLS)
$1,318.00
This Market Spotlight report covers the Tumor Lysis Syndrome (TLS) market, comprising key marketed and pipeline drugs, clinical trials, patent information, and a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Tumor Lysis Syndrome (TLS) market, comprising key marketed drugs, clinical trials, patent information, and a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2017, there were approximately 12,400 incident cases of tumor lysis syndrome (TLS) worldwide among individuals with high-risk malignancies (acute myeloid leukemia, acute lymphocytic leukemia, and Burkitt’s lymphoma).
- The number of incident cases is forecast to increase to 13,600 by 2026. The marketed drugs for TLS comprise the xanthine oxidase inhibitors Aloprim (allopurinol) and Uloric (febuxostat), and a recombinant urate-oxidase enzyme, Elitek (rasburicase). These therapies are administered via the intravenous and oral routes.
- The overall likelihood of approval of a Phase I hematologic asset is 10.1%, and the average probability a drug advances from Phase III is 57.7%. Drugs, on average, take 8.8 years from Phase I to approval, compared to 9.3 years in the overall oncology space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for TLS have been in the late phases of development, with 60% in Phase III–IV, and 40% in Phase II.
- The US has a substantial lead in the number of TLS clinical trials globally, while Italy and Spain lead the major EU markets. Clinical trial activity in the TLS space is dominated by completed trials. Sanofi has the highest number of completed clinical trials for TLS, with six in total.
- Sanofi has carried out the most clinical trials in the TLS space, with Menarini being the only other trial sponsor.
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
8 TREATMENT
8 Prophylaxis and monitoring
8 Volume expansion
8 Medical therapies
8 Renal replacement therapy
10 EPIDEMIOLOGY
10 Incidence assumptions
19 MARKETED DRUGS
21 PROBABILITY OF SUCCESS
22 PARENT PATENTS
23 REVENUE OPPORTUNITY
24 CLINICAL TRIAL LANDSCAPE
25 Sponsors by status
26 Sponsors by phase
27 BIBLIOGRAPHY
27 Prescription information
28 APPENDIX
LIST OF FIGURES
12 Figure 1: Trends in incident cases of TLS in selected high-risk malignancies, 2017–26
21 Figure 2: Probability of success in the TLS pipeline
24 Figure 3: Clinical trials in TLS
24 Figure 4: Top 10 drugs for clinical trials in TLS
25 Figure 5: Top 10 companies for clinical trials in TLS
25 Figure 6: Trial locations in TLS
26 Figure 7: TLS trials status
26 Figure 8: TLS trials sponsors, by phase
LIST OF TABLES
11 Table 1: Incident cases of TLS in selected high-risk malignancies, 2017–26
13 Table 2: Incidence of acute myeloid leukemia, and proportion of individuals with TLS, 2017
14 Table 3: Incident cases of TLS in acute myeloid leukemia, 2017–26
15 Table 4: Incidence of acute lymphocytic leukemia, and proportion of individuals with TLS, 2017
16 Table 5: Incident cases of TLS in acute lymphocytic leukemia, 2017–26
17 Table 6: Incidence of Burkitt’s lymphoma, and proportion of individuals with TLS, 2017
18 Table 7: Incident cases of TLS in Burkitt’s lymphoma, 2017–26
20 Table 8: Marketed drugs for TLS
22 Table 9: Parent patents in TLS
23 Table 10: Historical global sales, by drug ($m), 2014–18
23 Table 11: Forecasted global sales, by drug ($m), 2019–23
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the